Literature DB >> 24440572

Inappropriate expression of hepcidin by liver congestion contributes to anemia and relative iron deficiency.

Tomoyasu Suzuki1, Haruo Hanawa2, Shuang Jiao1, Yukako Ohno1, Yuka Hayashi1, Kaori Yoshida1, Takeshi Kashimura1, Hiroaki Obata1, Tohru Minamino1.   

Abstract

BACKGROUND: Anemia and relative iron deficiency (RID) are prevalent in patients with heart failure (HF). The etiology of anemia and RID in HF patients is unclear. Hepcidin expression may be closely related to anemia and RID in HF patients. Although hepcidin is produced mainly by the liver, and the most frequent histologic appearance of liver in HF patients is congestion, the influence of liver congestion (LC) on hepcidin production has not yet been investigated. We investigated whether hepcidin contributed to anemia and RID in rats with LC. METHODS AND
RESULTS: LC was induced in rats by ligating the inferior vena cava and compared with bleeding anemia (BA) model induced by phlebotomy and hemolytic anemia (HA) model induced by injection of phenylhydrazine. BA and HA strongly suppressed expression of hepcidin in liver and so did not cause decrease in serum iron and transferrin saturation. However, hepcidin expression did not decrease in LC rats, which resulted in anemia and lower transferrin saturation. In addition, many cells with hemosiderin deposits were observed in the liver and spleen and not in the bone marrow, and this appeared to be related to suppression of hepcidin expression. Iron accumulated in hepatocytes, and bone morphogenetic protein 6, which induces hepcidin, increased. Inflammation was observed in the congestive liver, and there was an increase in interleukin-6, which also induced hepcidin and was induced by free heme and hemoglobin via Toll-like receptor 4.
CONCLUSIONS: We conclude that LC contributes to RID and anemia, and it does so via inappropriate expression of hepcidin.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heart failure; Toll-like receptor 4; bone morphogenetic protein; cytokine

Mesh:

Substances:

Year:  2014        PMID: 24440572     DOI: 10.1016/j.cardfail.2014.01.008

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  6 in total

Review 1.  Towards Holistic Heart Failure Management-How to Tackle the Iron Deficiency Epidemic?

Authors:  Lucas N L Van Aelst; Dominiek Mazure; Alain Cohen-Solal
Journal:  Curr Heart Fail Rep       Date:  2017-08

Review 2.  In-depth review: is hepcidin a marker for the heart and the kidney?

Authors:  Rengin Elsurer Afsar; Mehmet Kanbay; Avsin Ibis; Baris Afsar
Journal:  Mol Cell Biochem       Date:  2021-05-04       Impact factor: 3.396

Review 3.  Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology.

Authors:  Driton Vela
Journal:  Lab Invest       Date:  2017-10-23       Impact factor: 5.662

4.  Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia.

Authors:  Patrícia Garrido; Sandra Ribeiro; João Fernandes; Helena Vala; Petronila Rocha-Pereira; Elsa Bronze-da-Rocha; Luís Belo; Elísio Costa; Alice Santos-Silva; Flávio Reis
Journal:  Int J Mol Sci       Date:  2015-12-25       Impact factor: 5.923

Review 5.  Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology.

Authors:  Ridha I S Alnuwaysir; Martijn F Hoes; Dirk J van Veldhuisen; Peter van der Meer; Niels Grote Beverborg
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.964

6.  Relationship between Cardiac Geometry and Serum Hepcidin in Chronic Kidney Disease: Analysis from the KNOW-CKD Study.

Authors:  Hyang Ki Min; Yun Kyu Oh; Kyu Hun Choi; Kyu Beck Lee; Sue K Park; Curie Ahn; Sung Woo Lee
Journal:  J Korean Med Sci       Date:  2020-01-06       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.